	Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial. Signal Transduct Target Ther Wu J, Li X, Gu C, Hua L, Liu R, Li J, Qiu M, Guo J, Dong H, Ji Z, Xie L, Zhu S, Zhang X, Chen P, Jiang S, Sun Z, Xu D, Chen H, Shi B, Wang Y, Pu J, Perabo F, Chen Y, Ye D. PMID: 41968137 [PubMed - indexed for MEDLINE]
	Re: Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski et al. Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304). Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.01.008. Eur Urol Oncol Tran PT, Deek MP, Sutera P. PMID: 41968037 [PubMed - as supplied by publisher]
	Radium-223 Treatment Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer: A Taiwan-Japan Collaborative Cohort Study. Biomed J Luo HL, Liu YY, Liu HY, Su YL, Chen YH, Ohyama C, Hatakeyama S, Kawaguch H, Aoki M, Chang YH, Wang HJ, Chen YT, Wu YT, Chang YL. PMID: 41967770 [PubMed - as supplied by publisher]
	Therapeutic sequencing and role of cabozantinib after immunotherapy in metastatic renal cell carcinoma. Crit Rev Oncol Hematol Catalano M, Venturini J, Vascotto IA, Sthembari K, Mancini S, Pratesi L, Paulet A, Mela MM, Rossi V, Pillozzi S, Antonuzzo L, Roviello G. PMID: 41967618 [PubMed - as supplied by publisher]
	Hypo fractionated Versus Conventional IMRT in Unfavorable Intermediate- and High-Risk Prostate Cancer: A Phase II Comparative Study of PSA Kinetics, Dosimetric and Toxicity Outcomes. Fr J Urol El-Din El-Behiri NSS, El-Din MAA, Alkady AM, Moussa RM, Elshebeny MM. PMID: 41967586 [PubMed - as supplied by publisher]
	Prognostic Significance of Circulating Tumor DNA in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer Ye D, Zhao Y, Yang L, Sun X, Cao T, Yuan M, Qiao T, Xing L, Sun X. PMID: 41966893 [PubMed - as supplied by publisher]
	Artificial Intelligence Across the PSMA Theranostic Continuum in Prostate Cancer. PET Clin Murugesan G, Moore S, Chang A, Mancini B, Kulkarni H. PMID: 41966892 [PubMed - as supplied by publisher]
	Gut microbiome impact on systemic therapy outcomes in metastatic renal cell carcinoma: a systematic review. World J Urol Gavi F, Bracco M, Testori N, Rossi F, Fettucciari D, Panio E, Assumma S, Russo P, Gandi C, Foschi N, Ragonese M, Turri F, Bientinesi R, Palermo G, Ciccarese C, Iacovelli R, Kröner PT, Gasbarrini A, Sighinolfi MC, Rocco B. PMID: 41966656 [PubMed - in process]
	MR-based techniques for imaging prostate cancer metabolism: current status and future perspectives. Abdom Radiol (NY) Cheng X, Xu J, Yao J, Song B. PMID: 41966642 [PubMed - as supplied by publisher]
	Impact of Dual Thyroid and Prostate Cancer Diagnosis on Patient Survival: Insights From a Large Cohort Study. Med Sci Monit Huang J, Jiang K, Zhu L, Chen W, Yu J, Chen M, Sang Y, Lv W. PMID: 41966052 [PubMed - indexed for MEDLINE]
	The miR-143/145 cluster in prostate cancer: molecular regulation, context-dependent functions, and medical implications. Biol Direct Stope MB, Erb HHH. PMID: 41965814 [PubMed - as supplied by publisher]
	Evaluation of the diagnostic value of three YiDiXie tests in prostate cancer: an observational prospective single-center study. Sci Rep Li X, Sun C, Lin S, Ge Z, Zhang P, Wang W, Chen S, Wu Y, Zhou H, Huang R, Ni L, Lai Y. PMID: 41965732 [PubMed - as supplied by publisher]
	Belzutifan Efficacy in Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma Versus Natural History Control Arm. J Natl Cancer Inst Linehan WM, Jemielita T, Cornell J, Chen K, Ball MW, Srinivasan R, Liu Y, Perini RF, Pinto CA. PMID: 41964905 [PubMed - as supplied by publisher]
	The prognostic value of the CALLY index in patients with metastatic hormone-sensitive prostate cancer. World J Urol Wei B, Chen G, Liu M, Gan S, Bai Z, Wang Z, Guo X, He J. PMID: 41964875 [PubMed - indexed for MEDLINE]
	Unequal Access to Novel Systemic Therapies for Bladder Cancer: A Global Analysis of Clinical Trials of Immune Checkpoint Inhibitors and Antibody-Drug Conjugates. Curr Urol Rep Angulo-Lozano JC, Calvillo-Ramirez A, Noyola-Perez A, Cojuc-Konigsberg G, Vaquera-Alfaro H, Anceno A, Suzman E, Sanchez-Musi LF, Ponce CFMS, Pichardo-Rojas P, Badin-Castro J, Abrahimi P, Scherr DS. PMID: 41964855 [PubMed - in process]
	Comparison of biopsy gleason pattern 4 percentage and length in grade group 2 prostate cancer patients. Virchows Arch Belisario YMG, Hollemans E, van Leenders GJLH. PMID: 41964720 [PubMed - as supplied by publisher]
	Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First-Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real-World Study (YUSHIMA Study). Int J Urol Muta R, Fukushima H, Tanaka H, Numao N, Nakamura Y, Yoshinaga A, Kawamura N, Yonese I, Izumi K, Yamamoto T, Uehara S, Suzuki K, Toide M, Takazawa R, Araki S, Yoshida S, Fujii Y. PMID: 41964179 [PubMed - indexed for MEDLINE]
	Mitophagy in bladder cancer: a double-edged sword in tumor progression and therapy. J Transl Med Chen Q, Chen T, Gan L, Lu Y, Qian B. PMID: 41963956 [PubMed - as supplied by publisher]
	Androgen receptor pathway inhibitor intensification in non-metastatic hormone-sensitive prostate cancer: current evidence and clinical implications. Clin Transl Oncol Willisch P, Vázquez-Barreiro B, Plata A, Belmonte IC, Guardia G, Del Castillo-Acuña R, Francolini G, Franzese C, Henríquez JDS, Couñago F, López-Campos F. PMID: 41963635 [PubMed - as supplied by publisher]
	Latin American Consensus for the Diagnosis and Treatment of Metastatic Castration-Sensitive Prostate Cancer. Clin Genitourin Cancer Losco F, Villareal Trujillo N, Jardim DL, Rodríguez-Covarrubias F, Perichón S, Bourlon MT, Martins da Trindade K, Villoldo G, Neciosup S, Sánchez H, Dominguez J, Ibatá L, Martínez-Rojas S, Kopp RM. PMID: 41963237 [PubMed - as supplied by publisher]

Articles 1 - 20 / 177422

Page 1 of 8872



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy